NCT00643916View on ClinicalTrials.gov

Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age

PHASE2CompletedINTERVENTIONAL
Enrollment

378

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

March 31, 2006

Study Completion Date

October 31, 2007

Conditions
MeningitisMeningococcal Infection
Interventions
BIOLOGICAL

Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)

0.5 mL, Intramuscular (at age 9 and 12 months)

BIOLOGICAL

Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)

0.5 mL, Intramuscular (at age 9 and 15 months)

BIOLOGICAL

Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)

0.5 mL, Intramuscular (at age 12 and 15 months)

BIOLOGICAL

Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)

0.5 mL, Intramuscular (at age 15 months)

BIOLOGICAL

Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)

0.5 mL, Intramuscular (at age 18 months)

BIOLOGICAL

A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)

0.5 mL, Subcutaneous (at 3 years to \<6 years of age)

Trial Locations (14)

15241

Pittsburgh

18960

Sellersville

19026

Drexel Hill

21201

Baltimore

30062

Marietta

30322

Atlanta

37664

Kingsport

40004

Bardstown

43205

Columbus

44308

Akron

72205

Little Rock

84123

Salt Lake City

06360

Norwich

01801

Woburn

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00643916 - Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age | Biotech Hunter | Biotech Hunter